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Background: Dexketoprofen trometamol plus tramadol hydrochloride is a new oral combination of two analgesics,
which have different mechanisms of action for the treatment of moderate to severe acute pain.
Methods: Randomised, double-blind, parallel, placebo and active-controlled, single and multiple-dose study
to evaluate the analgesic efficacy and safety of dexketoprofen/tramadol 25 mg/75 mg in comparison with the
single agents (dexketoprofen 25 mg and tramadol 100 mg) in moderate to severe acute pain after abdominal
hysterectomy.
Patients received seven consecutive doses of study drug within a 3-day period, each dose separated by an 8-hour
interval. A placebo arm was included during the single-dose phase to validate the pain model.
Efficacy assessments included pain intensity, pain relief, patient global evaluation and use of rescue medication.
The primary endpoint was the mean sum of pain intensity differences over the first 8 h (SPID8).
Results: The efficacy analysis included 606 patients, with a mean age of 48 years (range 25–73). The study results
confirmed the superiority of the combination over the single agents in terms of the primary endpoint (p <0.001).
Secondary endpoints were generally supportive of the superiority of the combination for both single and multiple
doses.
Most common adverse drug reactions (ADRs) were nausea (4.6 %) and vomiting (2.3 %). All other ADRs were
experienced by less than 2 % of patients.
Conclusions: The study results provided robust evidence of the superiority of dexketoprofen/tramadol 25 mg/
75 mg over the single components in the management of moderate to severe acute pain, as confirmed by the
single-dose efficacy, repeated-dose sustained effect and good safety profile observed.
Trial registration: EU Clinical Trials Register (EudraCT number 2012-004545-32, registered 04 October 2012);
Clinicaltrials.gov (NCT01904149, registered 17 July 2013).
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In patients with moderate to severe pain, it is difficult to
obtain effective analgesia with a single drug and, therefore,
analgesic drugs are commonly combined to achieve opti-
mal control of pain [1] as combination of analgesics are
often particularly effective [2]. Dexketoprofen trometamol
plus tramadol hydrochloride (dexketoprofen/tramadol) is
a new oral combination with features of dexketoprofen
(fast analgesic effect) and tramadol (long duration of
effect) to generate good analgesia at relatively low dosage
for the treatment of moderate to severe acute pain.
Dexketoprofen, a non-steroidal anti-inflammatory drug,
is a well-known peripheral analgesic drug characterised by
a quick onset of effect [3]. The trometamol salt ensures
rapid dissolution and absorption with early pain relief [4],
which is important for acute pain [5, 6]. Duration of pain
relief, however, is limited to 4 or 5 h [7]. Tramadol,
μ-opioid receptor agonist, noradrenaline and serotonin
re-uptake inhibitor, is a centrally-acting analgesic charac-
terised by a long duration of effect [8].
The combination of dexketoprofen and tramadol is ex-
pected to result in balanced peripheral-central analgesia
to allow for lower and better tolerated doses than the
single agents used alone. In particular, an additive effect
of dexketoprofen and tramadol is anticipated to result in
adequate analgesia from tramadol at lower doses than
recommended on its own for the treatment of moderate
to severe pain. In a previous dose-finding trial evaluating
four different dose-combinations of dexketoprofen and
tramadol versus placebo, the particular combination of
dexketoprofen 25 mg plus tramadol 75 mg demonstrated
a consistently superior efficacy in all parameters of anal-
gesia tested [9], and it was therefore selected as the
optimum combination of doses for further analysis.
The present study aimed to evaluate the analgesic effi-
cacy and safety of the single and repeated-dose adminis-
tration of dexketoprofen/tramadol 25 mg/75 mg oral fixed
combination in comparison with the single agents (trama-
dol given at a higher dose; 100 mg) in moderate to severe
acute pain after abdominal hysterectomy.
It was hypothesised that dexketoprofen/tramadol
25 mg/75 mg would provide a level of analgesia above
that achievable by each component alone, without com-
promising the safety profile.
Methods
The study (Sponsor Code DEX-TRA-04) was registered at
the EU Clinical Trials Register (EudraCT number 2012-
004545-32, registered 04 October 2012, URL: https://
www.clinicaltrialsregister.eu/ctr-search/search?query=eudr
act_number%3A2012-004545-32) and at Clinicaltrials.gov,
(NCT01904149, registered 17 July 2013, URL: https://
www.clinicaltrials.gov/ct2/show/NCT01904149?term=
dexketoprofen&rank=3.clinicaltrials.gov). It was performedat 28 study sites in eight European countries (Hungary,
Latvia, Lithuania, Poland, Romania, Russian Federation,
Slovakia and Spain). It was conducted in accordance
with the principles of Good Clinical Practice and the
Declaration of Helsinki and was approved by all the
concerned Competent Authorities and Ethics Committees
(Additional file 1). All participating patients provided writ-
ten informed consent. The clinical phase of the study
started on May 2013 (first patient screened) and con-
cluded on May 2014 (last patient out).
Patients
Female patients, aged 18 to 75 years, scheduled to
undergo a total or subtotal hysterectomy for benign con-
ditions, requiring an infraumbilical laparotomy of ≥3 cm
were eligible for the study. Patients were expected to
require hospitalisation for at least 3 days after surgery.
Criteria for randomisation included postoperative pain
of moderate to severe intensity (Visual Analogue Scale
[VAS] ≥40) the day after surgery.
Patients were excluded from the study in any of the
following circumstances: breastfeeding women, known
allergy or contraindication to the study drugs or rescue
medication, moderate to severe renal dysfunction, severe
hepatic or cardiac dysfunction, history of gastrointestinal
disorders, bleeding disorders, asthma, epilepsy, history
of drug or alcohol abuse or presence of any medical con-
dition that in the opinion of the investigator might pose
a risk to the patient or may confound study results. Con-
comitant use of analgesics (other than those specified in
the protocol) and any medications that could pose a risk
to the patient or confound the study results were re-
stricted within a period that depended on the half life of
the respective drugs. Further exclusion criteria encom-
passed surgical complications, chronic opioid use and
participation in any other clinical trial within the previ-
ous month.
Study design
It was a randomised, double-blind, double-dummy, par-
allel, placebo and active-controlled, single and multiple-
dose, phase III study, including a total of six treatment
arms (Table 1).
The overall study duration was approximately 6 weeks
for each patient, including the screening period (within
4 weeks of the randomisation day); the treatment period
(lasting 3 days) and the end of study visit (1 week after
the last dose) for final safety follow-up.
The treatment period consisted of a single-dose phase
(first 8 h after the first dose) followed by a multiple-dose
phase (subsequent six doses). Each dose of study medi-
cation was separated by an 8-hour interval. During the
single-dose phase, patients could receive one of four pos-
sible treatments (dexketoprofen/tramadol 25 mg/75 mg,
Table 1 Treatment arms
Study arm Single-dose phase
(first dose)
Multiple-dose phase
(subsequent six doses)
1 dexketoprofen/tramadol
25 mg/75 mg
dexketoprofen/tramadol
25 mg/75 mg
2 dexketoprofen 25 mg dexketoprofen 25 mg
3 tramadol 100 mg tramadol 100 mg
4 placebo dexketoprofen/tramadol
25 mg/75 mg
5 placebo dexketoprofen 25 mg
6 placebo tramadol 100 mg
The study included a total of six treatment arms, with an imbalanced 3:3:3:1:1:1
allocation ratio
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ing the multiple-dose phase, patients assigned to active
treatment were to remain on the same treatment arm
while patients assigned to placebo were to be re-allocated
to receive one of the three possible active treatments
(dexketoprofen/tramadol 25 mg/75 mg, dexketoprofen
25 mg or tramadol 100 mg). Overall, patients were to
receive seven consecutive doses of the study drug within a
3-day period.
For those patients who met the selection criteria, the
surgical procedure was performed following the study
site standard practice. Post-operative analgesia consisted
of morphine or other short-acting opioids administered
by intravenous or intramuscular route. On the day after
surgery, after cessation of the post-operative analgesia,
patients experiencing pain of moderate to severe inten-
sity (VAS ≥40) were randomised to receive the assigned
study treatment. A limit of 10 a.m. for randomisation
was set in order to harmonise the dosing schedule and
to allow the last dose on day 1 before midnight.
Participants were randomly assigned to one of six
treatment groups (see Table 1) following a blocked ran-
domisation procedure, with a block size of 12 and an
imbalanced allocation ratio of 3:3:3:1:1:1. At randomisa-
tion, patients were stratified in two categories of initial
pain intensity: moderate pain (VAS 40–60) or severe pain
(VAS >60). The randomisation process was centralised by
an Interactive Voice/Web Response System (IVRS/IWRS)
and the treatment code was delivered for each patient
according to a computer-generated random allocated se-
quence (randomisation list) prepared by a Sponsor’s third
party prior to the start of the study. Two sets were pre-
pared, one set was used for programming the IVRS/IWRS
and the other set was used for the labelling of the study
medication. Personnel involved in the preparation or the
handling of the randomisation list were not involved in
the study conduct and statistical analysis. Participants,
healthcare providers, and data collectors involved in the
conduct or statistical analysis were unaware of the treat-
ment participants were receiving. Moreover, double-blindconditions were secured by using a double-dummy design;
each study dose consisted of one tablet (containing
either dexketoprofen/tramadol 25 mg/75 mg, dexketo-
profen 25 mg, or placebo) and two capsules (containing
either tramadol 50 mg, or placebo).
Rescue medication (metamizole 500 mg, with a max-
imum recommended daily dose of 2 g) was available on
request during the entire treatment period. In addition,
during the multiple-dose phase, paracetamol 500 mg
could be used as an antipyretic.
Efficacy evaluation
Following treatment administration, patients were re-
quested to make multiple assessments of pain intensity
at rest and on movement (elicited pain upon sitting) and
of pain relief on an electronic diary (eDiary) over a
period of 3 days, with the last assessment to be recorded
8 h after the last dose of study drug. Patients also had to
make an overall assessment of the study medication
(patient global evaluation, PGE) at the end of each study
phase. The amount and the time when rescue medication
was used were also recorded.
Pain intensity was measured on a VAS (0–100) with
the left end labelled “no pain” and the right end labelled
“worst possible pain” [10, 11], pain relief was measured
on a five-point Verbal Rating Scale (VRS) (0 = none, 1 =
slight, 2 =moderate, 3 = good, 4 = complete) [10] and the
PGE was measured on a five-point VRS (1 = poor, 2 = fair,
3 = good, 4 = very good, 5 = excellent) [10, 12].
At baseline, pain intensity at rest and pain intensity on
movement were measured immediately before giving
study medication. During the single-dose phase, pain
intensity at rest and pain relief were measured at
30 min, 1, 1.5, 2, 3, 4, 6 and 8 h post-dose. During the
multiple-dose phase, pain intensity at rest and pain in-
tensity on movement were measured immediately before
the administration of each dose of study medication and
then every 2 and 4 h, respectively, with the last assess-
ment 8 h after the last dose of study medication, on the
third day. Whenever patients used rescue medication or
paracetamol, pain intensity and pain relief assessments
were recorded (when applicable) immediately before the
intake. If a patient withdrew from the study prematurely,
the PGE was also requested.
If escape analgesia (rescue medication) was used
during the single-dose phase, the Baseline Observation
Carried Forward method was applied [13], with pain
intensity returning to its baseline score and pain relief to
zero for all subsequent time points for the next 6 h. If
escape analgesia (rescue medication) or paracetamol was
used during the multiple-dose phase, the Last Observation
Carried Forward method was used instead (or the Worst
Observation Carried Forward method, if the assessment
immediately before was missing).
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total pain relief (TOTPAR) were calculated from the
pain intensity (VAS) and pain relief (VRS) scores. SPID
was calculated as the time-weighted sum of the pain
intensity difference (PID) values from baseline and TOT-
PAR was calculated as the time-weighted sum of the
pain relief scores. The percentages of the theoretical
maximum possible SPID (% max SPID) and of the theor-
etical maximum possible TOTPAR (% max TOTPAR)
were also calculated.
The primary efficacy endpoint was the mean SPID at
rest over 8 h after the first dose (SPID8). The primary
efficacy variable was used for the assessment of the
co-primary efficacy endpoint to test the superiority of
dexketoprofen/tramadol versus dexketoprofen and ver-
sus tramadol administered as single agents in the single-
dose phase.
Secondary efficacy endpoints during the single and
multiple-dose phases included: mean pain intensity
(VAS) scores, mean SPID, mean % max SPID, percent-
age of pain intensity responders (achievement of mean
pain intensity (VAS) <40), mean pain relief (VRS) scores,
mean TOTPAR, percentage of pain relief responders
(achievement of ≥50 % max TOTPAR), use of rescue
medication, time to use of rescue medication and PGE
at the end of each study phase.
Safety evaluation
The safety evaluation was based on the incidence, serious-
ness, intensity and causal relationship of spontaneously
reported treatment-emergent adverse events (AEs), i.e.
AEs occurred after the first study drug administration.
Furthermore, safety was also evaluated by the assessment
of clinically significant changes post-dose versus baseline
in physical examination, vital signs (blood pressure and
heart rate), 12-lead electrocardiogram (ECG) and labora-
tory safety tests (haematology, biochemistry and urinaly-
sis). Any patient who prematurely withdrew after having
received study medication was encouraged to undergo the
end of study visit.
Statistical analysis
For the primary efficacy variable, the null hypotheses
of equality between dexketoprofen/tramadol and dex-
ketoprofen and between dexketoprofen/tramadol and
tramadol in the single-dose phase were tested as co-
primary efficacy endpoints using an analysis of covari-
ance (ANCOVA) and a two-sided overall significance
level of 5 %. Treatment (as the main effect) and base-
line pain intensity (VAS) category were included as
covariates. No adjustment for multiplicity was required.
Comparison of dexketoprofen and tramadol versus pla-
cebo was tested in the same manner to validate the pain
model.Secondary efficacy variables were analysed as follows:
pain intensity (VAS), SPID, % max SPID and TOTPAR
(quantitative variables) were analyzed analogously to the
primary endpoint. Pain relief (VRS) and PGE (ordinal
variables) were analyzed by the Wilcoxon rank-sum test.
The percentage of responders (for both pain intensity
and pain relief ) were analysed using a Chi-square test.
In addition, the percentage of pain intensity responders
over 8 h was analysed using a general estimating equa-
tions (GEE) analysis. Time to rescue medication was
analyzed using the Kaplan-Meier estimation method and
treatment groups were compared using a log-rank test.
The percentage of patients using rescue medication was
analyzed using a Chi-square test.
It was estimated that a sample size of 600 evaluable
patients would be necessary for a power higher than
85 % and a significance level of 0.05 to detect the differ-
ence in change of SPID over 8 h from baseline between
dexketoprofen/tramadol and each single component. A
standard deviation of 94 mm*h and a between difference
of at least 35 mm*h was assumed based on previous
phase II study data (data on file). It was expected that
approximately 800 patients would have to be screened in
order to obtain 600 randomised patients, assuming an
approximate rate of 25 % screening failures.
Results
A total of 677 patients were screened, of which 606
patients were randomised and received the first dose of
the assigned study treatment, thus constituting the safety
population. Efficacy analyses were performed on the
“intention-to-treat” (ITT) population of the 606 rando-
mised patients. The “per protocol” (PP) population of
505 patients of the ITT population with no major proto-
col violations was used to perform confirmatory analyses
on the primary endpoint. Patient assignment to the dif-
ferent populations occurred before the study blind was
broken (Table 2).
The participant flow with the numbers of participants
who were randomly assigned, received intended treatment,
and were analysed for the primary outcome is represented
in Fig. 1.
Demography and baseline characteristics of different
treatment groups were comparable. Demographic and
baseline characteristics of the ITT population are repre-
sented in Table 3. The overall mean age was 48 years
(range 25–73 years). All patients were white. Initial pain
was moderate in 38 % patients and severe in 62 %
patients.
Thirty patients discontinued the study after randomisa-
tion (11 patients discontinued due to “lack of efficacy”, 11
patients due to “AEs”, one patient due to “protocol
violation”, one patient due to “non-compliance with
the study treatment” and six patients due to “withdrawal
Table 2 Analysis populations and patient disposition
N DKP/TRAM DKP TRAM Overall
SDP placebo SDP active All SDP placebo SDP active All SDP placebo SDP active All
ITT population 51 152 203 51 151 202 51 150 201 606
Safety population 52 151 203 50 152 202 51 150 201 606
PP population 43 127 170 42 129 171 40 124 164 505
N number of patients, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol
hydrochloride 100 mg, SDP single-dose phase, ITT intention-to-treat, PP per protocol. The ITT population included all patients randomised; the safety population
included all patients randomised who received at least one dose of study treatment; the PP population included all ITT patients with no major protocol violations
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the study.Efficacy results
Primary endpoint
The results of the primary analysis (SPID8; Fig. 2) con-
firmed the superiority of dexketoprofen/tramadol over
the single components (p <0.001). In addition, the com-
parisons of dexketoprofen and tramadol versus placebo
were both statistically significant (p <0.001 and p = 0.010,
respectively), confirming the model sensitivity.
Sensitivity analyses on the PP population confirmed
the primary efficacy results. The statistical analysis of SPID8
at rest by treatment is presented in Table 4.Secondary endpoints
The superiority of dexketoprofen/tramadol over the
single components with regards to mean pain intensity
(VAS) scores at rest during the single-dose phase was
observed at all time points (p <0.05), the only exception
being dexketoprofen/tramadol over dexketoprofen at the
1-hour time point (p = 0.13). The time course of the
mean pain intensity (VAS) at rest by treatment during
the single-dose phase is represented in Fig. 3.
During the multiple-dose phase, there was evidence of
lower mean pain intensity (VAS) scores at rest over 48 h
for dexketoprofen/tramadol than for both single compo-
nents, with statistical significance achieved over dexketo-
profen (p = 0.003). Similar results were seen for mean pain
intensity (VAS) on movement over 48 h (p <0.001 vs.
dexketoprofen). A mixed model for repeated measures
approach was applied for the analysis. The time course of
the mean pain intensity (VAS) at rest and on movement
by treatment during the multiple-dose phase is represented
in Figs. 4 and 5, respectively.
Analyses of mean SPID at rest over 2, 4 and 6 h
(SPID2, SPID4, SPID6) and over 24 and 48 h of the
multiple-dose phase (SPID24 and SPID48) confirmed the
superiority of dexketoprofen/tramadol over the single
components (p <0.05). Regarding mean SPID on move-
ment over 24 and 48 h, there was evidence of higher
scores on dexketoprofen/tramadol than on dexketoprofen
(p <0.001).Results are presented in Additional file 2 (summary)
and Additional file 3 (statistical analysis) for the single-
dose phase and in Additional file 4 (summary) and
Additional file 5 (statistical analysis) for the multiple-
dose phase. The time course of mean SPID at rest during
the single-dose phase is represented in Fig. 6.
Similarly, analyses of mean % max SPID at rest over 2,
4, 6, 8 h (% max SPID2, % max SPID4, % max SPID6, %
max SPID8) and over 24 and 48 h of the multiple-dose
phase (% max SPID24 and % max SPID48), confirmed the
superiority of dexketoprofen/tramadol over the single
components (p <0.05). In addition, analyses of mean %
max SPID on movement over 24 and 48 h confirmed
the superiority of dexketoprofen/tramadol over the single
agents (p <0.05).
Results are presented in Additional file 2 (summary)
and Additional file 3 (statistical analysis) for the single-dose
phase and in Additional file 4 (summary) and Additional
file 5 (statistical analysis) for the multiple-dose phase.
There was a significantly higher percentage of pain in-
tensity responders (achievement of mean pain intensity
VAS <40 mm) at rest for dexketoprofen/tramadol than
for the single components over the first 8 h (65 % for dex-
ketoprofen/tramadol vs. 46 % for dexketoprofen [p = 0.001]
and 41 % for tramadol [p <0.001]). During the multiple-
dose phase, the highest percentage of responders at rest
over 48 h was achieved with dexketoprofen/tramadol
(94 % for dexketoprofen/tramadol vs. 83 % for dexketopro-
fen [p <0.001] and 89 % for tramadol [p = 0.048]). Similar
results were seen for the response to treatment on move-
ment over 48 h (80 % for dexketoprofen/tramadol vs. 67 %
for dexketoprofen [p = 0.003] and 71 % for tramadol [p =
0.024]). Results are presented in Additional file 6 (single-
dose phase) and Additional file 7 (multiple-dose phase).
The superiority of dexketoprofen/tramadol over the
single agents with regards to mean pain relief (VRS)
scores during the single-dose phase was observed at all
time points (p <0.05), with the only exception of dexketo-
profen/tramadol over dexketoprofen at the 3-hour time
point (p = 0.062). The time course of the mean pain relief
(VRS) during the single-dose phase is represented in
Fig. 7.
The result of the analyses of mean TOTPAR (TOT-
PAR2, TOTPAR4, TOTPAR6, and TOTPAR8) confirmed
Fig. 1 Study CONSORT flow diagram. Participant flow with the numbers of participants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome. Five patients in the ITT population received incorrect kit study treatment: *one patient
was randomized to receive DKP (first dose placebo) but received DKP/TRAM (first dose placebo) instead; † one patient was randomized to receive
DKP/TRAM (first dose active) but received TRAM (first dose active) instead; ‡ one patient was randomized to receive DKP (first dose active) but
received TRAM (first dose placebo) instead; § one patient was randomized to receive TRAM (first dose placebo) but received DKP (first dose
active) instead; ¶ one patient was randomized to receive TRAM (first dose active) but received DKP (first dose active) instead. ** Received at least
one dose; alloc. allocated, ITT intention-to-treat, PP per protocol. The ITT population included all patients randomised; the safety population
included all patients randomised who received at least one dose of study treatment; the PP population included all ITT patients with no major
protocol violations; DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM
tramadol hydrochloride 100 mg; n: number of patients
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Table 3 Demographic and baseline characteristics (ITT population)
DKP/TRAM DKP TRAM Overall
SDP placebo
(N = 51)
SDP active
(N = 152)
All
(N = 203)
SDP placebo
(N = 51)
SDP active
(N = 151)
All
(N = 202)
SDP placebo
(N = 51)
SDP active
(N = 150)
All
(N = 201)
Overall
(N = 606)
Race N (%) White 51 (100 %) 152 (100 %) 203 (100 %) 51 (100 %) 151 (100 %) 202 (100 %) 51 (100 %) 150 (100 %) 201 (100 %) 606 (100 %)
Age (years) mean 47 48 48 47 47 47 47 48 48 48
SD 6.8 6.7 6.7 7.5 7.1 7.2 4.6 6.9 6.4 6.8
min 35 25 25 30 31 30 39 32 32 25
max 69 73 73 71 70 71 61 68 68 73
Height (cm) mean 165 164 164 164 164 164 164 164 164 164
SD 6.2 5.4 5.6 5.9 6.4 6.3 5.6 6.1 6.0 5.9
min 149 152 149 136 151 136 153 149 149 136
max 175 176 176 175 183 183 176 182 182 183
Weight (kg) mean 74 75 75 73 72 72 73 71 72 73
SD 14 15 15 15 14 14 11 12 12 14
min 52 48 48 50 45 45 50 49 49 45
max 114 120 120 112 110 112 90 106 106 120
Country Hungary 8 (16 %) 22 (15 %) 30 (15 %) 7 (14 %) 19 (13 %) 26 (13 %) 7 (14 %) 26 (17 %) 33 (16 %) 89 (15 %)
Latvia 7 (14 %) 22 (15 %) 29 (14 %) 4 (7.8 %) 17 (11 %) 21 (10 %) 5 (9.8 %) 17 (11 %) 22 (11 %) 72 (12 %)
Lithuania 1 (2.0 %) 2 (1.3 %) 3 (1.5 %) 1 (2.0 %) 4 (2.6 %) 5 (2.5 %) 3 (5.9 %) 3 (2.0 %) 6 (3.0 %) 14 (2.3 %)
Poland 18 (35 %) 63 (41 %) 81 (40 %) 23 (45 %) 53 (35 %) 76 (38 %) 17 (33 %) 60 (40 %) 77 (38 %) 234 (39 %)
Romania 10 (20 %) 32 (21 %) 42 (21 %) 12 (24 %) 40 (27 %) 52 (26 %) 12 (24 %) 32 (21 %) 44 (22 %) 138 (23 %)
Russian Federation 2 (3.9 %) 3 (2.0 %) 5 (2.5 %) 2 (3.9 %) 3 (2.0 %) 5 (2.5 %) 2 (3.9 %) 3 (2.0 %) 5 (2.5 %) 15 (2.5 %)
Slovakia 5 (9.8 %) 7 (4.6 %) 12 (5.9 %) 2 (3.9 %) 13 (8.6 %) 15 (7.4 %) 4 (7.8 %) 8 (5.3 %) 12 (6.0 %) 39 (6.4 %)
Spain 0 (0 %) 1 (0.7 %) 1 (0.5 %) 0 (0 %) 2 (1.3 %) 2 (1.0 %) 1 (2.0 %) 1 (0.7 %) 2 (1.0 %) 5 (0.8 %)
Baseline PI
(VAS) N (%)
moderate 19 (37 %) 59 (39 %) 78 (38 %) 19 (37 %) 58 (38 %) 77 (38 %) 19 (38 %) 57 (38 %) 76 (38 %) 231 (38 %)
severe 32 (63 %) 93 (61 %) 125 (62 %) 32 (63 %) 93 (62 %) 125 (62 %) 31 (62 %) 93 (62 %) 124 (62 %) 374 (62 %)
ITT intention-to-treat, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg, SDP single-dose phase, N number of
patients, SD standard deviation, PI pain intensity, VAS visual analogue scale. The ITT population included all randomised patients; PI was measured on a 0–100 VAS with the left end labelled “no pain” and the right end
labelled “worst possible pain”
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Fig. 2 Mean SPID over 8 h (single-dose phase) (Primary Endpoint). SPID summed pain intensity differences, DKP/TRAM dexketoprofen trometamol/
tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. Pain intensity (PI) was measured
on a 0–100 visual analogue scale (VAS) with left end labelled “no pain” and right end labelled “worst possible pain”; * statistically significant versus
both DKP and TRAM (p <0.001); † statistically significant versus placebo (p <0.05)
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components (p <0.05). Results are presented in Additional
file 8 (summary) and Additional file 9 (statistical analysis).
The result of the analyses confirmed the superiority of
dexketoprofen/tramadol over the single components in
terms of the percentage of responders with regards to
pain relief (achievement of at least 50 % max TOTPAR;
p <0.05 for all comparisons). Results are presented in
Additional file 10.
There was evidence of a longer overall time to first use of
rescue medication on dexketoprofen/tramadol comparedTable 4 Statistical analysis of SPID8 (single-dose phase) (Primary End
Population Point Estimate (SE)
(Treatment A)
Point Estimate
(SE) (TreatmenTreatment A Treatment B
ITT population
DKP/TRAM DKP 238 (11) 180 (11)
DKP/TRAM TRAM 238 (11) 153 (11)
DKP Placebo 180 (11) 112 (11)
TRAM Placebo 153 (11) 112 (11)
PP population
DKP/TRAM DKP 241 (12) 184 (12)
DKP/TRAM TRAM 241 (12) 160 (12)
DKP Placebo 184 (12) 123 (12)
TRAM Placebo 160 (12) 123 (12)
SPID8 summed pain intensity differences over 8 h post-dose, ANCOVA analysis of cova
75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg,
The ITT population included all patients randomised; the PP population included all IT
0–100 visual analogue scale (VAS) with the left end labelled “no pain” and the right en
the pain intensity difference (PID) values from baseline; SPID was tested using an ANCwith dexketoprofen (p = 0.003) and tramadol (p = 0.004) as
single agents. In addition, dexketoprofen/tramadol was
found to be superior to the single components (p = 0.008
and p = 0.001, respectively) with regards to the time to first
use of rescue medication during the single-dose phase.
The percentage of patients using rescue medication over
24 h during the multiple-dose phase was significantly lower
with dexketoprofen/tramadol (4.4 %) than with dexketopro-
fen (11 %; p = 0.010) and tramadol (10 %; p = 0.021). Results
were similar over 48 h (6.4 % versus 12 % and 12 %
respectively) and overall (7.9 % versus 13 % and 12 %point) (ANCOVA)
t B)
Estimated Treatment Difference
(SE) (Treatment A – Treatment B)
95 % CI p-value
58 (16) 27 to 88 <0.001
85 (16) 54 to 116 <0.001
68 (16) 37 to 99 <0.001
41 (16) 9.7 to 72 0.010
57 (17) 24 to 90 <0.001
81 (17) 48 to 115 <0.001
61 (17) 28 to 95 <0.001
37 (17) 3.2 to 70 0.032
riance, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/
SE standard error, CI confidence interval, ITT intention-to-treat, PP per protocol.
T patients with no major protocol violations; pain intensity (PI) was measured on a
d labelled “worst possible pain”; SPID was calculated as the time-weighted sum of
OVA and a two-sided overall significance level of 5 %
Fig. 3 Time course of mean PI (VAS) scores at rest (single-dose phase). PI pain intensity, VAS visual analogue scale, DKP/TRAM dexketoprofen
trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PI was measured
on a 0–100 VAS with left end labelled “no pain” and right end labelled “worst possible pain”; * statistically significant versus both DKP and TRAM
(p <0.05); † statistically significant versus TRAM only (p <0.05); ‡ statistically significant versus placebo (p <0.05)
Fig. 4 Time course of mean PI (VAS) scores at rest (multiple-dose phase). PI pain intensity, VAS visual analogue scale, DKP/TRAM dexketoprofen
trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PI was measured
on a 0–100 VAS with left end labelled “no pain” and right end labelled “worst possible pain”; statistical significance was achieved versus DKP (p = 0.003)
over the 48-hour multiple-dose period (mixed model for repeated measures approach)
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Fig. 5 Time course of mean PI (VAS) scores on movement (multiple-dose phase). PI pain intensity, VAS visual analogue scale, DKP/TRAM
dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg.
PI was measured on a 0–100 VAS with left end labelled “no pain” and right end labelled “worst possible pain”; pain on movement: elicited pain
upon sitting; Statistical significance was achieved versus DKP (p <0.001) over the 48-hour multiple-dose period (mixed model for repeated
measures approach)
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differences did not reach statistical significance.
Dexketoprofen/tramadol was found to be statistically
significantly superior to both single components in
terms of PGE scores for the single-dose phase (77 %Fig. 6 Time course of mean SPID at rest (single-dose phase). SPID summed
tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25
measured on a 0–100 visual analogue scale (VAS) with left end labelled “no
significant versus both DKP and TRAM (p <0.05); † statistically significant vepatients in the dexketoprofen/tramadol recorded a
“good”, “very good” or “excellent” response compared
with 64 % with dexketoprofen [p = 0.003] and 67 % pa-
tients with tramadol; [p <0.001]). Model sensitivity was
also confirmed. Results are presented in Additional file 11.pain intensity differences, DKP/TRAM dexketoprofen trometamol/
mg, TRAM tramadol hydrochloride 100 mg. Pain intensity (PI) was
pain” and right end labelled “worst possible pain”; * statistically
rsus placebo (p <0.05)
Fig. 7 Time course of mean PAR (VRS) scores (single-dose phase). PAR pain relief, VRS verbal rating scale, DKP/TRAM dexketoprofen trometamol/
tramadol hydrochloride 25 mg/75 mg, DKP dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg. PAR was measured on a
five-point VRS (0 = none, 1 = slight, 2 =moderate, 3 = good, 4 = complete) during the single-dose phase of the study; * statistically significant
versus both DKP and TRAM (p <0.05); † statistically significant versus TRAM only (p <0.05); ‡ statistically significant versus placebo (p <0.05)
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single agents could not be confirmed for the multiple-
dose phase of the study Additional file 12).
Safety results
Overall, 76 (13 %) patients reported a total of 100
adverse reactions (ADRs), of which 51 were mild, 42
were moderate and seven were severe. The most fre-
quent ADRs (≥2 % amongst the treatment group) were
nausea (4.6 % patients; 29 events), vomiting (2.3 % pa-
tients; 14 events), abdominal distension (1.5 % patients;
nine events), platelet count increased (1.3 % patients;
eight events) and blood lactate dehydrogenase increased
(1.0 % patients; six events) (Table 5).
The dexketoprofen/tramadol group presented a lower
incidence of ADRs (9.4 % patients) in comparison with
the dexketoprofen (15 % patients) and tramadol groups
(13 % patients). Overall, 11 (1.8 %) patients reported a
total of 15 serious adverse events (SAEs), of which only
one (psychotic disorder; in the dexketoprofen/trama-
dol group) was considered to be treatment-related.
There were no marked differences between treatment
groups in terms of safety outcomes, including vital
signs, physical examination, 12-lead ECG or laboratory
safety parameters. It was concluded that the study
treatments were safe and well tolerated and that the
dexketoprofen/tramadol combination showed a safety
profile fully in line with that previously known for the sin-
gle agents.Discussion
The study results confirmed that dexketoprofen/trama-
dol 25 mg/75 mg is able to provide a level of analgesia
above that achievable by each component alone and with
an extended duration of effect. Efficacy results were
consistent during single and multiple-dose phases, thus
supporting the selection of the doses and the regimen
proposed, which was based on a previous dose-finding
trial [9].
The proposed design was intended to fully characterise
the analgesic effect of the fixed combination as a single
dose as well as to confirm its sustained efficacy and to
evaluate its safety during the repeated administration.
Major abdominal surgery is a recognised model of mod-
erate to severe, acute pain, frequently used in the clinical
evaluation of analgesic drugs [14–19], though suggested
to be of lesser sensitivity than other models such as dental
extraction and bunionectomy [20].
A possible limitation of the study was the lack of a
sensitivity analysis during the multiple-dose phase. How-
ever, the inclusion of a placebo arm during the single-
dose phase only was considered as the least burdensome
approach for patients.
This was a large trial, conducted across eight different
countries and that included multiple investigational sites,
where the surgical technique and the anaesthetic regimen
could vary. Potential surgical confounders were reduced
by limiting the specific procedure type (hysterectomy)
and by allowing open procedure only (laparotomy).
Table 5 ADRs (active treatment) - by SOC/PT, by treatment group and overall
System organ class DKP/TRAM N
= 203
DKP N = 202 TRAM N = 201 Overall N =
606Preferred term
Gastrointestinal disorders 13 (6.4 %) | 14 17 (8.4 %) | 18 20 (10 %) | 27 50 (8.3 %) | 59
Nausea 8 (3.9 %) | 9 7 (3.5 %) | 7 13 (6.5 %) | 13 28 (4.6 %) | 29
Vomiting 2 (1.0 %) | 2 6 (3.0 %) | 6 6 (3.0 %) | 6 14 (2.3 %) | 14
Abdominal distension 2 (1.0 %) | 2 1 (0.5 %) | 1 6 (3.0 %) | 6 9 (1.5 %) | 9
Abdominal pain upper – 2 (1.0 %) | 2 – 2 (0.3 %) | 2
Constipation 1 (0.5 %) | 1 – 1 (0.5 %) | 1 2 (0.3 %) | 2
Dyspepsia – 2 (1.0 %) | 2 1 (0.5 %) | 1 3 (0.5 %) | 3
Investigations 2 (1.0 %) | 3 11 (5.4 %) | 17 4 (2.0 %) | 4 17 (2.8 %) | 24
Platelet count increased – 4 (2.0 %) | 4 4 (2.0 %) | 4 8 (1.3 %) | 8
Blood lactate dehydrogenase increased 1 (0.5 %) | 1 5 (2.5 %) | 5 – 6 (1.0 %) | 6
Gamma-glutamyltransferase increased 1 (0.5 %) | 1 3 (1.5 %) | 3 – 4 (0.7 %) | 4
Alanine aminotransferase increased – 2 (1.0 %) | 2 – 2 (0.3 %) | 2
Blood alkaline phosphatase increased 1 (0.5 %) | 1 1 (0.5 %) | 1 – 2 (0.3 %) | 2
Aspartate aminotransferase increased – 1 (0.5 %) | 1 – 1 (0.2 %) | 1
Hepatic enzyme increased – 1 (0.5 %) | 1 – 1 (0.2 %) | 1
Blood and lymphatic system disoders 1 (0.5 %) | 1 1 (0.5 %) | 1 1 (0.5 %) | 1 3 (0.5 %) | 3
Thrombocytosis 1 (0.5 %) | 1 1 (0.5 %) | 1 1 (0.5 %) | 1 3 (0.5 %) | 3
Vascular disorders 2 (1.0 %) | 3 – – 2 (0.3 %) | 3
Hypertension 1 (0.5 %) | 2 – – 1 (0.2 %) | 2
Hypertensive crisis 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Cardiac disorders 1 (0.5 %) | 1 1 (0.5 %) | 1 – 2 (0.3 %) | 2
Tachycardia 1 (0.5 %) | 1 1 (0.5 %) | 1 – 2 (0.3 %) | 2
Nervous system disorders – 1 (0.5 %) | 1 1 (0.5 %) | 1 2 (0.3 %) | 2
Dizziness – 1 (0.5 %) | 1 – 1 (0.2 %) | 1
Headache – – 1 (0.5 %) | 1 1 (0.2 %) | 1
Psychiatric disorders 1 (0.5 %) | 1 1 (0.5 %) | 1 – 2 (0.3 %) | 2
Insomnia – 1 (0.5 %) | 1 – 1 (0.2 %) | 1
Psychotic disorder 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Skin and subcutaneous tissue disorders 1 (0.5 %) | 1 – 1 (0.5 %) | 1 2 (0.3 %) | 2
Pruritus – – 1 (0.5 %) | 1 1 (0.2 %) | 1
Urticaria 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Ear and labyrinth disorders – – 1 (0.5 %) | 1 1 (0.2 %) | 1
Vertigo – – 1 (0.5 %) | 1 1 (0.2 %) | 1
General disorders and administration site conditions 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Asthenia 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Metabolism and nutrition disorders 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Hypokalaemia 1 (0.5 %) | 1 – – 1 (0.2 %) | 1
Overall 19 (9.4 %) | 26 30 (15 %) | 39 27 (13 %) | 35 76 (13 %) | 100
ADR adverse drug reaction, SOC system organ class, PT preferred term, DKP/TRAM dexketoprofen trometamol/tramadol hydrochloride 25 mg/75 mg, DKP
dexketoprofen trometamol 25 mg, TRAM tramadol hydrochloride 100 mg, N number of patients. “Active treatment” refers to events arising after first dose of
active drug intake (i.e. DKP|TRAM, DKP or TRAM); Results are expressed as number of patients (% of exposed) | number of events
Moore et al. BMC Anesthesiology  (2016) 16:9 Page 12 of 14Furthermore, the restriction to non-malignant conditions
additionally ensured the homogeneity of the study popula-
tion. Other important factors, such as the postoperativeanalgesic care were standardized, and only those patients
experiencing a certain level of pain intensity on the day
after surgery were included in the study.
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primary endpoint including ‘country’ or ‘site’ as add-
itional covariates. A significant (p <0.0001) effect, prob-
ably related to some low-recruiting sites and countries,
was detected in both cases. However, the differences
between treatment arms remained significant (p <0.01) for
all comparisons.
The individual rating of pain intensity is highly sub-
jective and has significant inter- and intra-individual
variability. The inclusion of multiple efficacy assessments
(pain intensity, pain relief, PGE) and outcomes was
aimed to capture the extent of the analgesia that is being
produced in the postoperative context. An overall con-
sistency among different outcomes is judged to be more
relevant than any particular result.
Pain intensity upon sitting was not recorded during
the single-dose phase to avoid unnecessary interferences
with pain at rest measurements given that SPID8 at rest
was the primary endpoint.
As for the safety results, the combination presented a
safety profile fully consistent with what was previously
reported for dexketoprofen and tramadol when used as
single agents for short term use. No increase of AEs was
observed; in fact, the incidence of ADRs with the fixed-
dose combination was slightly lower than with both single
agents alone.
Conclusion
The study results provided robust evidence of the efficacy
of dexketoprofen/tramadol 25 mg/75 mg in the manage-
ment of moderate to severe acute pain, as confirmed by
the single-dose efficacy, the repeated-dose sustained effect
and the good safety profile observed.
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